Nicotinamide Mononucleotide (NMN) as a Novel Therapeutic in the Treatment of Oral Mucositis

烟酰胺单核苷酸（NMN）作为治疗口腔粘膜炎的新疗法

基本信息

批准号：
9770831
负责人：
DAVID A. SINCLAIR
金额：
$ 21.19万
依托单位：
HARVARD MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-09-01 至 2020-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9770831
关键词：
3-Dimensional Acute Analgesics Animals Anti-inflammatory Antiinflammatory Effect Apoptosis Apoptotic Attenuated Basal Cell Biological Assay Cancer Patient Cell Culture Techniques Cell physiology Cells Cellular Morphology Cheek structure Clinical Paths DNA Damage DNA Repair Enzymes Development Enzymes Epithelial Epithelium Gastrointestinal tract structure Gold Hamsters Head and Neck Cancer Health Hematopoietic Stem Cell Transplantation Human In Vitro Inflammasome Inflammation Inflammatory Inflammatory Response Isotope Labeling Lead Maintenance Measures Mediating Medical Research Metabolic Mitochondria Modeling Molecular Morphology Mucositis Mucous Membrane Mus Nicotinamide Mononucleotide Nicotinamide adenine dinucleotide Oral Oral Pathology Oral cavity Oral mucous membrane structure Outcome Patients Poly(ADP-ribose) Polymerases Quality of life Radiation Radiation therapy Reactive Oxygen Species Resolution Role SIRT1 gene Secondary to Severities Signaling Protein Sirtuins Stratum Basale Study models Supportive care Testing Tissues Toxic effect Treatment Efficacy Ulcer Whole-Body Irradiation antimicrobial cancer therapy chemoradiation chemotherapeutic agent chemotherapy cost cytotoxicity disabling symptom dosage effective therapy experimental study gastrointestinal gastrointestinal epithelium histological stains improved in vivo inhibitor/antagonist irradiation knock-down novel novel therapeutics oral mucositis outcome forecast prevent regenerative response secondary infection senescence side effect

项目摘要

SUMMARY Despite advances in the development of targeted chemotherapeutic agents, oral mucositis secondary to conventional chemotherapy and radiation remains one of the most frequently encountered toxicities associated with cancer therapy. It leads to both costly and debilitating symptoms and, in severe cases, a worsened prognosis for the patient. Oral mucositis occurs in up to 100% of cases of head and neck cancer and 60 – 90% of cases of hematopoietic stem cell transplants. Acute DNA damage caused by conventional chemotherapy and radiation leads to rapid hyperactivation of a group of DNA-repairing enzymes known as poly-ADP-ribose polymerases (PARPs) that utilize nicotinamide adenine dinucleotide (NAD+) as a co-substrate. The depletion of NAD+ leads to a decrease in the activity of SIRT1, an NAD+-dependent deacylase that suppresses inflammation. In the past few years, NAD+ precursors have emerged as one of the most exciting molecules in medical research. We hypothesize that maintenance of NAD+ levels in oral mucosa by treatment with the NAD+ precursor nicotinamide mononucleotide (NMN) will greatly reduce the inflammatory cascade and greatly reduce the severity and duration of oral mucositis, providing a novel path to preventing and treating this debilitating condition. To test this hypothesis we will perform both in vitro and in vivo studies modeling the pathology of oral mucositis. In Aim 1, we will study the protective and anti-inflammatory effects of NMN in in vitro oral cells and trace the flux of NAD+ using isotopically labeled NMN. In Aim 2 we will utilize a hamster radiation-induced oral mucositis model to evaluate if topical NMN delays the onset, reduces the peak, dampens the total extent, and promotes resolution of mucositis. In Aim 3 we will explore the mechanisms by which NMN attenuates mucositis by testing if SIRT1 is a key regulator of oral mucositis that mediates the anti- inflammatory activities of NMN. These experiments will systematically evaluate whether an NAD+ precursor can effectively mitigate oral mucositis and guide the development of safe and effective treatments to cut the costs of cancer treatment in the US and significantly improve quality of life for cancer patients.

概括尽管靶向化疗药物的开发取得了进展，但继发于口腔粘膜炎传统化疗和放疗仍然是最常见的相关毒性之一癌症治疗会导致昂贵且令人衰弱的症状，在严重的情况下，还会导致病情恶化。高达 100% 的头颈癌病例和 60-90% 的病例都会发生口腔粘膜炎。传统化疗引起的急性 DNA 损伤的病例。辐射会导致一组称为聚 ADP 核糖的 DNA 修复酶快速过度激活利用烟酰胺腺嘌呤二核苷酸 (NAD+) 作为辅助底物的聚合酶 (PARP)。 NAD+ 导致 SIRT1 活性降低，SIRT1 是一种 NAD+ 依赖性脱酰酶，可抑制在过去的几年中，NAD+前体已成为炎症领域最令人兴奋的分子之一。我们致力于通过 NAD+ 治疗来维持口腔粘膜中的 NAD+ 水平。前体烟酰胺单核苷酸（NMN）将大大减少炎症级联反应，并大大减少减少口腔粘膜炎的严重程度和持续时间，为预防和治疗口腔粘膜炎提供了新途径为了检验这一假设，我们将进行体外和体内研究模拟。在目标 1 中，我们将研究 NMN 的保护和抗炎作用。体外口腔细胞并使用同位素标记的 NMN 追踪 NAD+ 的通量。在目标 2 中，我们将利用仓鼠。放射诱发的口腔粘膜炎模型，用于评估局部 NMN 是否可以延迟发作、降低峰值、在目标 3 中，我们将通过以下方式探索其机制。 NMN 通过测试 SIRT1 是否是口腔粘膜炎的关键调节因子（介导抗- 这些实验将系统地评估 NAD+ 前体是否存在。可以有效缓解口腔粘膜炎，并指导开发安全有效的治疗方法以减少口腔粘膜炎的发生。降低美国癌症治疗费用，并显着提高癌症患者的生活质量。